间充质干细胞在慢性肺部疾病中的临床应用。
Clinical applications of mesenchymal stem cells in chronic lung diseases.
作者信息
Antoniou Katerina M, Karagiannis Konstantinos, Tsitoura Eliza, Bibaki Eleni, Lasithiotaki Ismini, Proklou Athanasia, Spandidos Demetrios A, Tzanakis Nikos
机构信息
Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion 71110, Crete, Greece.
Department of Thoracic Medicine, Interstitial Lung Disease Unit, University Hospital, University of Crete, Heraklion 71110, Crete, Greece.
出版信息
Biomed Rep. 2018 Apr;8(4):314-318. doi: 10.3892/br.2018.1067. Epub 2018 Feb 16.
Abstract
Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair . The therapeutic potential of expanded MSCs are currently under investigation for a variety of chronic and acute lung diseases. This review summarizes the encouraging results regarding the safety of MSCs administration from recent and current clinical trials for idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and chronic obstructive pulmonary disease. It also reviews the early preliminary data extracted by the same trials regarding the efficacy of MSCs in the aforementioned lung diseases.
摘要
间充质干细胞（MSC）是多能基质细胞，具有调节对组织损伤的免疫反应并促进修复的能力。目前正在研究扩增后的MSC对多种急慢性肺部疾病的治疗潜力。本综述总结了近期和当前针对特发性肺纤维化、急性呼吸窘迫综合征和慢性阻塞性肺疾病的临床试验中有关MSC给药安全性的令人鼓舞的结果。它还回顾了这些试验提取的关于MSC在上述肺部疾病中疗效的早期初步数据。
相似文献
1
Clinical applications of mesenchymal stem cells in chronic lung diseases.间充质干细胞在慢性肺部疾病中的临床应用。
Biomed Rep. 2018 Apr;8(4):314-318. doi: 10.3892/br.2018.1067. Epub 2018 Feb 16.
2
Mesenchymal stem cells in the treatment of chronic lung disease.间充质干细胞在慢性肺病治疗中的应用
Respirology. 2016 Nov;21(8):1366-1375. doi: 10.1111/resp.12911. Epub 2016 Sep 29.
3
Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease.间充质干细胞/基质细胞衍生产品在肺部疾病中的治疗潜力。
Respir Res. 2018 Nov 9;19(1):218. doi: 10.1186/s12931-018-0921-x.
4
Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science.慢性阻塞性肺疾病患者间充质干细胞给药：科学现状
Stem Cells Int. 2017;2017:8916570. doi: 10.1155/2017/8916570. Epub 2017 Feb 20.
5
The Role of Lung Resident Mesenchymal Stromal Cells in the Pathogenesis and Repair of Chronic Lung Disease.肺固有间充质基质细胞在慢性肺部疾病发病机制和修复中的作用。
Stem Cells. 2023 May 15;41(5):431-443. doi: 10.1093/stmcls/sxad014.
6
Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome.最新见解：间充质基质/干细胞疗法治疗急性呼吸窘迫综合征
F1000Res. 2016 Jun 28;5. doi: 10.12688/f1000research.8217.1. eCollection 2016.
7
Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives.基于间充质干细胞的炎症性肺部疾病治疗：当前认识与未来展望
Stem Cells Int. 2019 May 2;2019:4236973. doi: 10.1155/2019/4236973. eCollection 2019.
8
Mesenchymal stem cells in idiopathic pulmonary fibrosis.特发性肺纤维化中的间充质干细胞
Oncotarget. 2017 May 23;8(60):102600-102616. doi: 10.18632/oncotarget.18126. eCollection 2017 Nov 24.
9
Current therapeutic strategies for respiratory diseases using mesenchymal stem cells.使用间充质干细胞治疗呼吸系统疾病的当前策略。
MedComm (2020). 2021 Sep 2;2(3):351-380. doi: 10.1002/mco2.74. eCollection 2021 Sep.
10
Mesenchymal stem cell trials for pulmonary diseases.间充质干细胞治疗肺部疾病的试验
J Cell Biochem. 2014 Jun;115(6):1023-32. doi: 10.1002/jcb.24783.
引用本文的文献
1
Mesenchymal Stem Cells and Tissue Bioengineering Applications in Sheep as Ideal Model.绵羊作为理想模型中骨髓间充质干细胞与组织生物工程应用
Stem Cells Int. 2024 Oct 18;2024:5176251. doi: 10.1155/2024/5176251. eCollection 2024.
2
Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.特发性肺纤维化的细胞疗法：当前进展与未来前景
Am J Stem Cells. 2024 Aug 25;13(4):191-211. doi: 10.62347/DAKS5508. eCollection 2024.
3
Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.脂肪源性间充质干细胞治疗结缔组织疾病及并发症。
Inflamm Regen. 2024 Jul 19;44(1):35. doi: 10.1186/s41232-024-00348-z.
4
Melatonin and mesenchymal stem cells co-administration alleviates chronic obstructive pulmonary disease via modulation of angiogenesis at the vascular-alveolar unit.褪黑素和间充质干细胞共同给药通过调节血管肺泡单元的血管生成缓解慢性阻塞性肺疾病。
Pflugers Arch. 2024 Jul;476(7):1155-1168. doi: 10.1007/s00424-024-02968-3. Epub 2024 May 14.
5
Regenerative and translational medicine in COPD: hype and hope.COPD 中的再生和转化医学：炒作与希望。
Eur Respir Rev. 2023 Jul 26;32(169). doi: 10.1183/16000617.0223-2022. Print 2023 Sep 30.
6
Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review.肺部疾病中的间充质干细胞及其在 COVID-19 急性呼吸窘迫综合征中的潜在应用：系统评价。
Clinics (Sao Paulo). 2023 Jul 14;78:100237. doi: 10.1016/j.clinsp.2023.100237. eCollection 2023.
7
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.间充质干细胞在 COVID-19 治疗中的潜在治疗应用机制。
Cell Transplant. 2023 Jan-Dec;32:9636897231184611. doi: 10.1177/09636897231184611.
8
Regenerative medicine in lung diseases: A systematic review.肺部疾病中的再生医学：一项系统综述。
Front Vet Sci. 2023 Jan 17;10:1115708. doi: 10.3389/fvets.2023.1115708. eCollection 2023.
9
Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial.自体骨髓和间充质基质细胞输注治疗慢性阻塞性肺疾病患者：I 期随机临床试验。
Int J Chron Obstruct Pulmon Dis. 2021 Dec 29;16:3561-3574. doi: 10.2147/COPD.S332613. eCollection 2021.
10
Lung-Resident Mesenchymal Stem Cell Fates within Lung Cancer.肺癌中的肺驻留间充质干细胞命运
Cancers (Basel). 2021 Sep 16;13(18):4637. doi: 10.3390/cancers13184637.
本文引用的文献
1
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.静脉输注异体人骨髓间充质干细胞治疗特发性肺纤维化（AETHER）：一项I期安全性临床试验
Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24.
2
A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.一项针对重度肺气肿患者静脉注射自体间充质基质细胞的I期研究。
QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.
3
Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study.胎盘来源的间充质样细胞（PDA - 001）用于慢性结节病的治疗：一项1期研究。
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jul 22;32(2):106-14.
4
Study of Bone Marrow and Embryonic Stem Cell-Derived Human Mesenchymal Stem Cells for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in Mice.骨髓和胚胎干细胞来源的人间充质干细胞治疗小鼠大肠杆菌内毒素诱导的急性肺损伤的研究
Stem Cells Transl Med. 2015 Jul;4(7):832-40. doi: 10.5966/sctm.2015-0006. Epub 2015 May 21.
5
Intravenous Transplantation of BMP2-Transduced Endothelial Progenitor Cells Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats.BMP2转导的内皮祖细胞静脉移植减轻大鼠脂多糖诱导的急性肺损伤
Cell Physiol Biochem. 2015;35(6):2149-58. doi: 10.1159/000374020. Epub 2015 Apr 7.
6
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.间充质干细胞（基质）治疗 ARDS：1 期临床试验。
Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17.
7
Bone marrow-derived progenitor cells attenuate inflammation in lipopolysaccharide-induced acute respiratory distress syndrome.骨髓来源的祖细胞可减轻脂多糖诱导的急性呼吸窘迫综合征中的炎症反应。
BMC Res Notes. 2014 Sep 8;7:613. doi: 10.1186/1756-0500-7-613.
8
A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis.一项关于胎盘来源间充质基质细胞治疗特发性肺纤维化患者的1b期研究。
Respirology. 2014 Oct;19(7):1013-8. doi: 10.1111/resp.12343. Epub 2014 Jul 9.
9
Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.异体脂肪间充质干细胞治疗急性呼吸窘迫综合征的随机、安慰剂对照初步研究。
Respir Res. 2014 Apr 4;15(1):39. doi: 10.1186/1465-9921-15-39.
10
Expansive generation of functional airway epithelium from human embryonic stem cells.从人类胚胎干细胞中生成功能性气道上皮细胞。
Stem Cells Transl Med. 2014 Jan;3(1):7-17. doi: 10.5966/sctm.2013-0119. Epub 2013 Dec 3.
Zotero 插件